BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27179656)

  • 1. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Endocrine; 2016 Oct; 54(1):129-138. PubMed ID: 27179656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Exp Mol Pathol; 2015 Dec; 99(3):492-7. PubMed ID: 26403329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Exp Cell Res; 2015 Dec; 339(2):342-50. PubMed ID: 26384552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
    Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
    Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
    Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.
    Zerilli M; Zito G; Martorana A; Pitrone M; Cabibi D; Cappello F; Giordano C; Rodolico V
    Mod Pathol; 2010 Aug; 23(8):1052-60. PubMed ID: 20473281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
    Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
    Liu D; Liu Z; Condouris S; Xing M
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
    Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
    BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
    J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
    Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
    Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
    Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.